Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors - a single center experience . (2015). Clinics, 70(8), 550-555. https://doi.org/10.6061/clinics/2015(08)04